SCHEMBL1347532

SCHEMBL1347532

O=C(NNC(=S)Nc1cccc(C(F)(F)F)c1)c1sccc1Br

nearest known ligand 0.62

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.62
MAPT P10636 8/20 0.62
GAA P10253 7/20 0.62
TDP1 Q9NUW8 4/20 0.62
NPSR1 Q6W5P4 3/20 0.62
TASP1 Q9H6P5 1/20 0.59
MEN1 O00255 6/20 0.58
KMT2A Q03164 6/20 0.58
LMNA P02545 5/20 0.58
HTT P42858 4/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
RAB9A P51151 1/20 0.55
KDM4E B2RXH2 1/20 0.54
AHSA1 O95433 1/20 0.53
IDO1 P14902 1/20 0.50
HPGD P15428 1/20 0.50
ALOX12 P18054 1/20 0.50
BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1344731 0.90 MAPT (0.56) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL1345296 0.82 RAB9A (0.60) ALDH1A1MAPTGAATDP1MEN1
SCHEMBL1346518 0.81 ALDH1A1 (0.75) ALDH1A1MAPTGAATDP1NPSR1
SCHEMBL1344833 0.76 MAPT (0.53) ALDH1A1MAPTGAANPSR1MEN1
SCHEMBL28640537 0.76 ALDH1A1 (0.80) ALDH1A1MAPTGAATDP1NPSR1
SCHEMBL17799175 0.76 ALDH1A1 (0.64) ALDH1A1MAPTGAATDP1NPSR1
SCHEMBL1344924 0.75 MAPT (0.55) ALDH1A1MAPTGAAMEN1KMT2A
SCHEMBL4438310 0.75 ALDH1A1 (0.61) ALDH1A1MAPTGAATDP1MEN1
SCHEMBL10069116 0.74 TASP1 (1.00) ALDH1A1MAPTGAATDP1NPSR1
SCHEMBL7175227 0.73 MAPT (0.86) ALDH1A1MAPTGAATDP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-8063034-B2 Oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-11-22 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128156-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITING ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016354-A1 NOVEL OXADIAZOLE DERIVATIVES AND THIADIAZOLE DERIVATIVES HAVING NEOVASCULARIZATION INHIBITORY ACTIVITY FLT4, VEGFA, FLT1 ALDH1A1 232/4885MAPT 4800/4885GAA 3849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.